Abstract | BACKGROUND: METHODS: RESULTS: We show that inhibiting ATM increased cytotoxicity of PARP inhibitor in triple-negative and non- triple-negative breast cancer cell lines, and depleting the cells of 53BP1 reduced this cytotoxicity. Inhibiting ATM abrogated homologous recombination induced by PARP inhibitor, and down-regulating 53BP1 partially reversed this effect. Further, overall survival was significantly better in triple-negative breast cancer patients with lower levels of phospho-ATM and tended to be better in patients with negative 53BP1. CONCLUSION: These results suggest that 53BP1 may be a predictor of PARP inhibitor resistance in patients with ATM-deficient tumors.
|
Authors | Ruoxi Hong, Fei Ma, Weimin Zhang, Xiying Yu, Qing Li, Yang Luo, Changjun Zhu, Wei Jiang, Binghe Xu |
Journal | BMC cancer
(BMC Cancer)
Vol. 16
Issue 1
Pg. 725
(09 09 2016)
ISSN: 1471-2407 [Electronic] England |
PMID | 27613518
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one
- Morpholines
- Phthalazines
- Piperazines
- Poly(ADP-ribose) Polymerase Inhibitors
- Pyrones
- TP53BP1 protein, human
- Tumor Suppressor p53-Binding Protein 1
- ATM protein, human
- Ataxia Telangiectasia Mutated Proteins
- olaparib
|
Topics |
- Apoptosis
- Ataxia Telangiectasia Mutated Proteins
(deficiency, metabolism)
- Breast Neoplasms
(genetics, metabolism)
- Cell Line, Tumor
- Cell Proliferation
(drug effects)
- Cell Survival
(drug effects)
- Drug Resistance, Neoplasm
- Drug Synergism
- Female
- Gene Expression Regulation, Neoplastic
- Gene Knockdown Techniques
- Humans
- MCF-7 Cells
- Morpholines
(pharmacology)
- Phosphorylation
- Phthalazines
(pharmacology)
- Piperazines
(pharmacology)
- Poly(ADP-ribose) Polymerase Inhibitors
(pharmacology)
- Prognosis
- Pyrones
(pharmacology)
- Survival Analysis
- Tumor Suppressor p53-Binding Protein 1
(genetics, metabolism)
|